Study #2018-1094
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabagene Autocleucel (GAVO-CEL) in Patients with Advanced Mesothelin-Expressing Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab
Description
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mesothelioma, Mesothelioma, Malignant, Mesothelioma, Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
Study phase:
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.